Advertisement

Addition of Glofitamab to R-CHOP or Pola-R-CHP in Younger Patients With High-Risk LBCL


Advertisement
Get Permission

In an Australian phase II trial (COALITION) reported in the Journal of Clinical Oncology, Minson et al investigated the addition of glofitamab to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) or Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone) as first-line therapy in younger patients with high-risk large B-cell lymphoma (LBCL).
Study Details
In the multicenter open-label trial, 80 patients aged ≤ 65 years (median = 58 years) received one cycle of R-CHOP and were randomly assigned between July 2021 and July 2023 to receive five cycles of glofitamab plus either R-CHOP (n = 40) or Pola-R-CHP (n = 40), followed by two cycles of glofitamab consolidation.
 
Key Findings
Median follow-up was 20.7 months.
Among all patients, the overall response rate was 100%, with complete metabolic response in 98%; a partial metabolic response was observed in one patient in each group.
Among all patients, 2-year progression-free survival was 86% (95% confidence interval [CI] = 75%–93%), including 86% (95% CI = 69%–94%) in the glofitamab plus R-CHOP group and 86% (95% CI = 65%–95%) in the glofitamab plus Pola-R-CHP group.
Among all patients, 2-year overall survival was 92% (95% CI = 80%–97%), including 92% (95% CI = 76%–97%) in the glofitamab plus R-CHOP group and 91% (95% CI = 67%–98%) in the glofitamab plus Pola-R-CHP group.
Grade ≥ 3 adverse events occurred in 56% of patients in both the R-CHOP group and the Pola-R-CHP group, including infection in 19% of all patients (15% and 23%). Serious adverse events occurred in 46% of all patients (43% and 50%). Cytokine-release syndrome was observed in 21% of all patients (20% and 23%; all grade ≤ 2).
The investigators concluded: “The combination of glofitamab with R-CHOP or Pola-R-CHP is deliverable and results in high rates of durable response in this population of younger patients with high-burden, [high-risk LBCL], supporting its ongoing exploration as a [first-line] treatment.”
Michael J. Dickinson, MBBS, DMSc, of Peter MacCallum Cancer Centre, Melbourne, Australia, is the corresponding author for the Journal of Clinical Oncology article.
Disclosure: The study was supported by F. Hoffmann–La Roche, Roche Diagnostics, and others. For full disclosures of all study authors, visit the Journal of Clinical Oncology.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
Advertisement

Advertisement




Advertisement